TY - JOUR
T1 - Responsible Research and Innovation Framework, the Nagoya Protocol and Other European Blue Biotechnology Strategies and Regulations
T2 - Gaps Analysis and Recommendations for Increased Knowledge in the Marine Biotechnology Community
AU - Schneider, Xenia Theodotou
AU - Stroil, Belma Kalamujić
AU - Tourapi, Christiana
AU - Rebours, Céline
AU - Gaudêncio, Susana P.
AU - Novoveska, Lucie
AU - Vasquez, Marlen I.
N1 - Funding Information:
info:eu-repo/grantAgreement/FCT/6817 - DCRRNI ID/UIDP%2F04378%2F2020/PT#
This publication is based upon work from COST Action CA18238 (Ocean4Biotech), funded by the European Cooperation in Science and Technology (COST) Program in the period 2019–2023.
The work of Stroil, B.K was cofounded by the COST Action CA18238 through the Virtual Mobility grant. project LA/P/0140/2020 of the Associate Laboratory Institute for Health and Bioeconomy—i4HB. This work is also financed by the Research Council of Norway (NCR319577SAFERIMTA) and Møreforsking AS.
Publisher Copyright:
© 2022 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2022/4/26
Y1 - 2022/4/26
N2 - As the quest for marine-derived compounds with pharmacological and biotechnological potential upsurges, the importance of following regulations and applying Responsible Research and Innovation (RRI) also increases. This article aims at: (1) presenting an overview of regulations and policies at the international and EU level, while demonstrating a variability in their implementation; (2) highlighting the importance of RRI in biodiscovery; and (3) identifying gaps and providing recommendations on how to improve the market acceptability and compliance of novel Blue Biotechnology compounds. This article is the result of the work of the Working Group 4 “Legal aspects, IPR and Ethics” of the COST Action CA18238 Ocean4Biotech, a network of more than 130 Marine Biotechnology scientists and practitioners from 37 countries. Three qualitative surveys (“Understanding of the Responsible Research and Innovation concept”, “Application of the Nagoya Protocol in Your Research”, and “Brief Survey about the experiences regarding the Nagoya Protocol”) indicate awareness and application gaps of RRI, the Nagoya Protocol, and the current status of EU policies relating to Blue Biotechnology. The article categorises the identified gaps into five main categories (awareness, understanding, education, implementation, and enforcement of the Nagoya Protocol) and provides recommendations for mitigating them at the European, national, and organisational level.
AB - As the quest for marine-derived compounds with pharmacological and biotechnological potential upsurges, the importance of following regulations and applying Responsible Research and Innovation (RRI) also increases. This article aims at: (1) presenting an overview of regulations and policies at the international and EU level, while demonstrating a variability in their implementation; (2) highlighting the importance of RRI in biodiscovery; and (3) identifying gaps and providing recommendations on how to improve the market acceptability and compliance of novel Blue Biotechnology compounds. This article is the result of the work of the Working Group 4 “Legal aspects, IPR and Ethics” of the COST Action CA18238 Ocean4Biotech, a network of more than 130 Marine Biotechnology scientists and practitioners from 37 countries. Three qualitative surveys (“Understanding of the Responsible Research and Innovation concept”, “Application of the Nagoya Protocol in Your Research”, and “Brief Survey about the experiences regarding the Nagoya Protocol”) indicate awareness and application gaps of RRI, the Nagoya Protocol, and the current status of EU policies relating to Blue Biotechnology. The article categorises the identified gaps into five main categories (awareness, understanding, education, implementation, and enforcement of the Nagoya Protocol) and provides recommendations for mitigating them at the European, national, and organisational level.
KW - blue biotechnology
KW - convention on biological diversity
KW - legal and ethical compliance workflow
KW - marine biotechnology
KW - marine genetic resources
KW - marine micro-and macro-organisms
KW - marine natural products
KW - Nagoya Protocol
KW - policy recommendations
KW - Responsible Research and Innovation (RRI)
KW - sustainable blue economy
UR - http://www.scopus.com/inward/record.url?scp=85129709648&partnerID=8YFLogxK
U2 - 10.3390/md20050290
DO - 10.3390/md20050290
M3 - Article
C2 - 35621941
AN - SCOPUS:85129709648
SN - 1660-3397
VL - 20
JO - Marine Drugs
JF - Marine Drugs
IS - 5
M1 - 290
ER -